Abstract
Immune checkpoint blockade (ICB) has revolutionized the landscape of cancer treatment. Nevertheless, most cancer patients still do not respond to ICB. In this issue of Cancer Cell, Blomberg et al. illustrate a critical cooperation between T cells and eosinophils, which jointly enhance effectiveness of ICB in breast cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 9-11 |
| Number of pages | 3 |
| Journal | Cancer Cell |
| Volume | 41 |
| Issue number | 1 |
| DOIs |
|
| State | Published - 9 Jan 2023 |
Funding
| Funders | Funder number |
|---|---|
| Azrieli Foundation Canada-Israel | |
| Cancer Biology Research Center | |
| Dotan Hemato Oncology fund | |
| Richard Eimert Research Fund on Solid Tumors | |
| U.S.-Israel Bi-national Science Foundation | 2015163 |
| Israel Cancer Research Fund | |
| Israel Cancer Association | |
| Israel Science Foundation | 886/15, 542/20 |
| Tel Aviv University |
